Listen and follow our podcasts on:

Bayer

Listen to a deep-dive into optimising treatment sequencing for patients with metastatic colorectal cancer, 3rd line and beyond, from Dr Jenny Seligmann and Dr Shubham Pant.

In the podcast, the experts discuss what clinicians should consider when making treatment decisions. You'll learn about

  • the potential treatment options for patients with advanced mCRC
  • the latest available data
  • which patient considerations are important when making treatment decisions

 

Clinical Takeaways

  • Molecular profiling has an important role in determining treatment options and sequence

  • Physicians should consider patient characteristics, such as comorbidities, toxicities from prior treatments, and overall performance status

  • Treatment from earlier lines of therapy is critical to treatment decisions in the 3rdline and beyond

  • There are a lot of new developments in the third-line treatment space for mCRC patients

  • Patients should receive as many treatment options as possible, and this should be considered during sequencing decisions

Dr Jenny Seligmann gained her MBChB and BMedSci at the University of Aberdeen in 2005 then gained her PhD in 2015 from the University of Leeds on Biomarkers of Prognosis and Prediction of Response in Colorectal Cancer. She was appointed a Cancer Research UK Clinical Trials Fellow in 2015, then a University Academic Fellow and Consultant in Medical Oncology in Leeds in 2017. Her research interests are in clinical trials and biomarkers of prediction of response in colorectal cancer. She is involved in several ongoing clinical trials, including the FOCUS-4 trial and has an ongoing lab-based programme of research. She has been involved in several national and international committees, including the UK Colorectal Clinical Studies Group and is currently the EORTC GI Group Young Investigator. She has received several awards including an ASCO Merit Award in 2013.

Prof. Jenny Seligmann has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Merck Serono, Pierre Fabre and Roche Diagnostics. 

Dr. Shubham Pant is a Professor in the Department of Gastrointestinal (GI) Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics (Phase I Center) at The University of Texas MD Anderson Cancer Center. Dr. Pant is recognised as an international expert in GI cancers with an emphasis on pancreatic and biliary cancers and Phase 1 trials.

 

Dr. Pant's research focuses on novel immunotherapeutic approaches and targeted therapies in GI cancers, including devising novel ways to target the KRAS mutation. He has been the lead/co-lead of several global practice-changing studies, including 'Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicenter, single-arm, phase 2b study'; 'Adagrasib in advanced solid tumors harboring a KRASG12C mutation' and 'Erdafitinib in patients with advanced solid tumors with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study'; amongst others. He has over 100 peer-reviewed publications and has published in high-impact journals, including The Lancet, Lancet Oncology, and Journal of Clinical Oncology. He is frequently invited to present his research at national and international meetings. He collaborates on numerous grants, including R01 and SPORE grants funded by the National Institute of Health. Dr. Pant serves on the National Cancer Institute (NCI) Pancreas Task Force and the Pancreatic Cancer Action Network's (PanCan) Scientific and Medical Advisory Board. He also helped draft the American Society of Clinical Oncology (ASCO) Metastatic Pancreatic Cancer Guidelines, which provide evidence-based recommendations for physicians. He is also the editor of the book Pancreatic Cancer: Current Therapeutics and Future Directions (Publisher: Springer).

Prof. Shubham Pant has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Alligator Bioscience, Amal Therapeutics, Arcus, AskGene Pharma, Astellas, AstraZeneca, BioNTech, Boehringer Ingelheim, BPGBio, Bristol-Myers Squibb, Elicio, Framewave, Immuneering, ImmunoMET, Ipsen, Janssen, Jazz, Lilly, Mirati Therapeutics, NGM Pharmaceuticals, Nihon Medi-Physics Co, Ltd, Novartis, Pfizer, Revolution Medicine, Theriva Biosciences, USWorldmeds, Zymeworks

Experts
Prof. Sebastian Stintzing, Dr Juan Manuel O'Connor
  • download Downloadable
    Resouces
  • clock 9 MIN
  • calendar Jan 2023
  • Non-accredited Independent Medical Education
This educational programme is supported by an Independent Educational Grant from Bayer

Listen and follow our podcasts on:

Bayer

Listen to a deep-dive into optimising treatment sequencing for patients with metastatic colorectal cancer, 3rd line and beyond, from Dr Jenny Seligmann and Dr Shubham Pant.

In the podcast, the experts discuss what clinicians should consider when making treatment decisions. You'll learn about

  • the potential treatment options for patients with advanced mCRC
  • the latest available data
  • which patient considerations are important when making treatment decisions

 

Clinical Takeaways

  • Molecular profiling has an important role in determining treatment options and sequence

  • Physicians should consider patient characteristics, such as comorbidities, toxicities from prior treatments, and overall performance status

  • Treatment from earlier lines of therapy is critical to treatment decisions in the 3rdline and beyond

  • There are a lot of new developments in the third-line treatment space for mCRC patients

  • Patients should receive as many treatment options as possible, and this should be considered during sequencing decisions

Dr Jenny Seligmann gained her MBChB and BMedSci at the University of Aberdeen in 2005 then gained her PhD in 2015 from the University of Leeds on Biomarkers of Prognosis and Prediction of Response in Colorectal Cancer. She was appointed a Cancer Research UK Clinical Trials Fellow in 2015, then a University Academic Fellow and Consultant in Medical Oncology in Leeds in 2017. Her research interests are in clinical trials and biomarkers of prediction of response in colorectal cancer. She is involved in several ongoing clinical trials, including the FOCUS-4 trial and has an ongoing lab-based programme of research. She has been involved in several national and international committees, including the UK Colorectal Clinical Studies Group and is currently the EORTC GI Group Young Investigator. She has received several awards including an ASCO Merit Award in 2013.

Prof. Jenny Seligmann has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Merck Serono, Pierre Fabre and Roche Diagnostics. 

Dr. Shubham Pant is a Professor in the Department of Gastrointestinal (GI) Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics (Phase I Center) at The University of Texas MD Anderson Cancer Center. Dr. Pant is recognised as an international expert in GI cancers with an emphasis on pancreatic and biliary cancers and Phase 1 trials.

 

Dr. Pant's research focuses on novel immunotherapeutic approaches and targeted therapies in GI cancers, including devising novel ways to target the KRAS mutation. He has been the lead/co-lead of several global practice-changing studies, including 'Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicenter, single-arm, phase 2b study'; 'Adagrasib in advanced solid tumors harboring a KRASG12C mutation' and 'Erdafitinib in patients with advanced solid tumors with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study'; amongst others. He has over 100 peer-reviewed publications and has published in high-impact journals, including The Lancet, Lancet Oncology, and Journal of Clinical Oncology. He is frequently invited to present his research at national and international meetings. He collaborates on numerous grants, including R01 and SPORE grants funded by the National Institute of Health. Dr. Pant serves on the National Cancer Institute (NCI) Pancreas Task Force and the Pancreatic Cancer Action Network's (PanCan) Scientific and Medical Advisory Board. He also helped draft the American Society of Clinical Oncology (ASCO) Metastatic Pancreatic Cancer Guidelines, which provide evidence-based recommendations for physicians. He is also the editor of the book Pancreatic Cancer: Current Therapeutics and Future Directions (Publisher: Springer).

Prof. Shubham Pant has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Alligator Bioscience, Amal Therapeutics, Arcus, AskGene Pharma, Astellas, AstraZeneca, BioNTech, Boehringer Ingelheim, BPGBio, Bristol-Myers Squibb, Elicio, Framewave, Immuneering, ImmunoMET, Ipsen, Janssen, Jazz, Lilly, Mirati Therapeutics, NGM Pharmaceuticals, Nihon Medi-Physics Co, Ltd, Novartis, Pfizer, Revolution Medicine, Theriva Biosciences, USWorldmeds, Zymeworks

Experts
Prof. Sebastian Stintzing, Dr Juan Manuel O'Connor
  • clock MIN
  • calendar Jan 2023
  • Non-accredited Independent Medical Education
This educational programme is supported by an Independent Educational Grant from Bayer
Programme summary
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.  

Meet the experts Independent IME approved
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.  

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update
Oncology 
Highlights from ASCO 2025

Coming Soon: Expert insights on the latest data 

Experts
Prof. Mark Socinski, Dr Elizabeth Smyth, Dr Paolo Tarantino, Dr Domenica Lorusso, Prof. Gerhardt Attard
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • clock 1 MIN
  • calendar May 2025

The oncogene-addicted NSCLC supported through an Independent Educational Grant from Bayer with all other updates supported by COR2ED
symposium Symposium
Oncology 
ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer

Experts
Prof. Wolfgang Janni, Prof. Sherko Kümmel, Prof. Michail Ignatiadis
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Serie de podcasturi referitoare la gestionarea trombozei

Experți de renume din domeniul medical își împărtășesc perspectivele. Navigați în secțiuni pentru a selecta un episod al podcastului 

Experts
Prof. Dimitrios Tsakiris, Dr Lars Asmis, Prof. Jerzy Windyga, Prof. Daniel Bolliger
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar May 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
video Video
Oncology Hemato-oncology 
Optimising the sequence of novel therapies from early relapse in multiple myeloma

Improving the survival of patients with relapsed/refractory multiple myeloma

Experts
Prof. Hermann Einsele, Prof. Evangelos Terpos
  • download Downloadable
    Resources
  • clock 2 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
animated-video Animated Video
Oncology 
BRAF V600E mutated NSCLC: The evolving treatment landscape

Expert insights into personalised treatment strategies in BRAF-mutated NSCLC

Experts
Prof. Amanda Tufman
Endorsed by
BRAF Bombers ICAN international cancer advocacy network Biomarker Collaborative
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar May 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
podcast Podcast
Oncology 
Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC)

Chemotherapy strategies that matter

Experts
Prof. Shubham Pant, Prof. Efrat Dotan
Endorsed by
DiCE ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from Ipsen USA